BPC February 04 update

Stock offerings for ZIOP and RAPT; Pipeline updates for GILD NBIX following 4Q earnings

Price and Volume Movers

Tuesday saw a quiet day in terms of major price-moving newsflow, with just a couple offerings noted below. Gilead and Neurocrine Biosciences reported earnings after the bell, with respective pipeline updates noted below.

-

Ziopharm Oncology, Inc. (NASDAQ:ZIOP) announced after hours that it intends to offer and sell shares of its common stock in an underwritten registered public offering. Shares are trading down 13% to $3.42 after hours.

Rapt Therapeutics, Inc. (NASDAQ:RAPT) shares are trading down 3% to $41.00 after hours after it also announced it has commenced an underwritten public offering of 2m shares of its common stock.

ContraFect Corporation (NASDAQ:CFRX) announced a 1-for-10 reverse stock split of its shares of common stock, effective today.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Puma Biotechnology, Inc. (PBYI): $10.58; +32%.

La Jolla Pharmaceutical Company (LJPC): $8.39; +22%.

Aduro BioTech, Inc. (ADRO): $2.24; +20%.

BeyondSpring Inc. (BYSI): $17.70; +19%.

Tonix Pharmaceuticals Holding Corp. (TNXP): $1.63; +17%.

Marker Therapeutics, Inc. (MRKR): $3.04; +17%.

DECLINERS:

Vaxart, Inc. (VXRT): $1.18; -26%.

Miragen Therapeutics, Inc. (MGEN): $1.19; -17%.

Cleveland BioLabs, Inc. (CBLI): $2.44; -16%.

Savara Inc. (SVRA): $2.24; -16%.

Annovis Bio, Inc. (ANVS): $6.12; -16%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AVRO – AVROBIO Inc.
AVR-RD-04
Cystinosis

Phase 1/2 Phase 1/2 update February. 10, 2020, noted no safety concerns.
$696.7 million

AVRO – AVROBIO Inc.
AVR-RD-01 (FAB-201)
Fabry disease

Phase 1/2 Phase 2 trial ongoing.
$696.7 million

CLSN – Celsion Corporation
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer

Phase 3 Phase 3 second analysis 2Q 2020.
$29.1 million

CTXR – Citius Pharmaceuticals Inc.
Mino-Lok
Catheter related blood stream infection

Phase 3 Phase 3 75% interim analysis for superior efficacy expected 1H 2020.
$26.6 million

GILD – Gilead Sciences Inc.
Axicabtagene ciloleucel - (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 Phase 2 data due 1H 2020.
$92.2 billion

GILD – Gilead Sciences Inc.
Axicabtagene ciloleucel (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)

Phase 3 Phase 3 data due 2H 2020.
$92.2 billion

GILD – Gilead Sciences Inc.
Axicabtagene ciloleucel - KTE-C19 and utomilumab (ZUMA-11)

Phase 1 Phase 1 trial ongoing.
$92.2 billion

GILD – Gilead Sciences Inc.
Axicabtagene ciloleucel - (ZUMA-12)
Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Phase 2 data due 2021.
$92.2 billion

GLPG – Galapagos NV
Filgotinib - SELECTION
Ulcerative colitis

Phase 3 Phase 3 data due 2Q 2020.
$15.9 billion

GLPG – Galapagos NV
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis

Phase 3 Phase 3 futility analysis data due 1Q 2021.
$15.9 billion

GLPG – Galapagos NV
GLPG1972 - ROCCELLA
Osteoarthritis

Phase 2b Phase 2b data due 2H 2020.
$15.9 billion

NBIX – Neurocrine Biosciences Inc.
NBI-921352 (XEN901)
SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)

Phase 2 Phase 2 trial to commence 2H 2020.
$8.9 billion

NBIX – Neurocrine Biosciences Inc.
ACT-709478
Pediatric epilepsy

Phase 2 Phase 2 trial to commence 2H 2020.
$8.9 billion